Close Menu

NEW YORK – Switzerland-based Basilea Pharmaceutica on Wednesday announced that it has partnered with Eli Lilly to evaluate its FGFR inhibitor derazantinib with Lilly's anti-VEGFR2 antibody ramucirumab (Cyramza) as a treatment for patients with FGFR-altered, advanced gastric cancer.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.